Global Cancer Immunotherapies Market to 2022 - Immune Checkpoint Inhibitors and Therapeutic Cancer Vaccines to Characterize Increasingly Competitive Market

  • ID: 4027220
  • Report
  • Region: Global
  • 363 Pages
  • GBI Research
1 of 6
The Market Size for Cancer Immunotherapies is Expected to Grow More than Fourfold from $16.9 Billion in 2015 to $75.8 Billion by 2022, Representing a Rapid CAGR of 23.9%

FEATURED COMPANIES

  • Amgen
  • AstraZeneca
  • Bristol-Myers Squibb
  • Celgene
  • Kite Pharma
  • Merck & Co.
  • MORE
Cancer is a group of diseases characterized by abnormal cell growth. It is a multi-step process, as a single mutation is almost certainly insufficient to cause a cell to become malignant. A number of cellular processes must be deregulated to allow cells to proliferate uncontrollably while evading apoptosis. Initially, key cell growth, proliferative and pro-apoptotic signaling pathways are deregulated in most cancers. These signaling pathways enable cell survival, continued proliferation, and the avoidance of programmed cell death.

Cancer immunotherapy, which can predominantly be classed as a form of targeted therapy, drives an immune response against cancer cells. This may include stimulating a patient’s immune system in a general way or aiding the identification of specific antigens associated with the cancer. The interest in cancer immunotherapy development has been driven by the growing understanding of the immune system as a hallmark of cancer pathophysiology, particularly immune evasion of developing cancer cells.

The market size for cancer immunotherapies is expected to grow at an exceptional rate over the forecast period, from $16.9 Billion in 2015 to $75.8 Billion in 2022, at a compound annual growth rate (CAGR) of 23.9%. The forecast for the most optimistic outcome has the market reach $82.1 Billion in 2022, at a CAGR of 25.3%. The US market is forecast to grow at a similarly rapid rate, from $9.5 Billion in 2015 to $40.8 Billion in 2022, which equates to just over half of the total market size throughout the forecast period.

Overall, there are 2,037 products in active development in the cancer immunotherapy pipeline. This makes it a notable portion of the entire oncology pipeline, and reflects the strong interest in this class of therapy in product development. This is due to the growing clinical rationale behind developing such therapies, and the willingness of drug developers to invest in novel therapeutics, which will offer significant product differentiation from market competitors.

According to Yasser Mushtaq, “Although the cancer immunotherapy pipeline is clearly strong, a significant proportion is made up of early-stage products, namely those from the Discovery stage to Phase I. This is indicative of the difficulty associated with progressing cancer immunotherapies from preclinical laboratory studies to clinical application in humans.”

The report “Global Cancer Immunotherapies Market to 2022 - Immune Checkpoint Inhibitors and Therapeutic Cancer Vaccines to Characterize Increasingly Competitive Market” provides an introduction to key indications within cancer immunotherapies, including disease epidemiology, symptoms, pathophysiology, diagnosis and disease staging and prognosis.

In depth, it provides the following:
  • Provides an overview of the marketed products landscape, including product profiles of key marketed products and revenue projections for each of these drugs.
  • Analyzes the cancer immunotherapies pipeline, detailing, among other parameters, drug distribution by stage of development, molecule type and molecular target, plus an analysis of the key indications in the pipeline: breast cancer, melanoma, NSCLC and ovarian cancer.
  • Presents forecast projections to 2022 on a global level, with forecasts provided for the US, plus aggregate revenue forecasts of the top five EU markets (the UK, France, Germany, Italy and Spain) and Japan.
  • Assesses the company landscape, with an analysis of the key players, the types of company involved in this therapy area, and whether this therapy area comprises a large proportion of each company’s pipeline portfolio and total revenues.
  • Analyzes trends in co-development and licensing deals, relating to cancer immunotherapy products.
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Amgen
  • AstraZeneca
  • Bristol-Myers Squibb
  • Celgene
  • Kite Pharma
  • Merck & Co.
  • MORE

1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Therapy Area Introduction
2.2 Epidemiology
2.2.1 Breast Cancer
2.2.2 Melanoma
2.2.3 Non-Small-Cell Lung Cancer
2.2.4 Ovarian Cancer
2.3 Pathophysiology and Etiology
2.3.1 Breast Cancer
2.3.2 Melanoma
2.3.3 Non-Small-Cell Lung Cancer
2.3.4 Ovarian Cancer
2.4 Symptoms
2.4.1 Breast Cancer
2.4.2 Melanoma
2.4.3 NSCLC
2.4.4 Ovarian Cancer
2.5 Diagnosis and Disease Staging
2.5.1 Breast Cancer
2.5.2 Melanoma
2.5.3 Non-Small-Cell Lung Cancer
2.5.4 Ovarian Cancer
2.6 Prognosis
2.6.1 Breast Cancer
2.6.2 Melanoma
2.6.3 Non-Small-Cell Lung Cancer
2.6.4 Ovarian Cancer
2.7 Treatment

3 Key Marketed Products
3.1 Overview
3.2 Rituxan/MabThera - Roche
3.3 Revlimid (lenalidomide) - Celgene
3.4 Yervoy (ipilimumab) - Bristol-Myers Squibb
3.5 Opdivo (nivolumab) - Bristol-Myers Squibb
3.6 Keytruda (pembrolizumab) - Merck & Co.
3.7 Pomalyst (pomalidomid) - Celgene
3.8 Gardasil/Gardasil 9 (human papillomavirus [types 6, 11, 16, 18] (quadrivalent) vaccine-prophylactic vaccine) - Merck & Co.
3.9 Provenge (sipuleucel-T) - Valeant Pharmaceuticals
3.10 Conclusion

4 Pipeline Landscape Assessment
4.1 Overview
4.2 Pipeline Development Landscape
4.3 Molecular Targets in the Pipeline
4.4 Clinical Trials
4.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
4.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
4.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target
4.4.4 Aggregate Clinical Program Size by Stage of Development, Indication, Molecule Type and Molecular Target
4.4.5 Conclusion
4.5 Assessment of Key Pipeline Products
4.5.1 Durvalumab - AstraZeneca
4.5.2 Durvalumab + Tremelimumab - AstraZeneca
4.5.3 Tisagenlecleucel-T (CTL-019) - Novartis
4.5.4 KTE-C19 - Kite Pharma
4.5.5 Avelumab - Merck KGaA/Pfizer
4.5.6 Epacadostat - Incyte Corporation
4.5.7 Conclusion

5 Multi-scenario Market Forecast to 2022
5.1 Overall Market Size
5.2 Generic Penetration
5.3 Revenue Forecast by Molecular Target
5.3.1 Immune-Checkpoint Proteins
5.3.2 Tumor Associated Antigens
5.3.3 Cancer Vaccines
5.3.4 Signal Transduction
5.4 Revenue and Market Share Analysis by Company
5.4.1 Celgene - Revlimid to Maintain Celgene’s Position as Market Leader
5.4.2 Bristol-Myers Squibb - Opdivo to Drive Revenue from Cancer Immunotherapies
5.4.3 Roche - Revenue Generated from Cancer Immunotherapies Forecast to Grow due to Tecentriq and Gazyva
5.4.4 Merck & Co. - Keytruda Key to Cancer Immunotherapy Market Growth
5.4.5 AstraZeneca - New Approvals to Mark Entry of AstraZeneca in Cancer Immunotherapy Market
5.4.6 Novartis - Cancer Immunotherapies Constitute Small Proportion of Vast Overall Revenue
5.4.7 Amgen - Innovative Imlygic to Help Generate above $1 Billion from Cancer Immunotherapy Market
5.4.8 Pfizer - Overall Cancer Immunotherapy Revenue to Surpass $1 Billion by 2022 due to PD-L1-Inhibitor Avelumab
5.4.9 Kite Pharma - KTE-C19 CAR to Drive Revenue Growth in Forecast Period

6 Company Analysis and Positioning
6.1 Company Landscape
6.2 Marketed and Pipeline Portfolio Analysis

7 Strategic Consolidations
7.1 Licensing Deals
7.1.1 Deal by Region, Year and Value
7.1.2 Deals by Stage of Development and Value
7.1.3 Deals by Molecule Type, Molecular Target and Value
7.1.4 Table for Licensing Deals Valued above $500m
7.2 Co-development Deals
7.2.1 Deals by Region, Year and Value
7.2.2 Deals by Stage of Development and Value
7.2.3 Deals by Molecule Type, Mechanism of Action and Value
7.2.4 Table for Co-development Deals Valued above $100m

8 Appendix
8.1 Bibliography
8.2 All Pipeline Drugs by Phase of Development
8.2.1 Discovery
8.2.2 Preclinical
8.2.3 IND/CTA-filed
8.2.4 Phase I
8.2.5 Phase II
8.2.6 Phase III
8.2.7 Pre-registration
8.2.8 Unknown
8.3 Abbreviations
8.4 Disease List
8.5 Methodology
8.5.1 Coverage
8.5.2 Secondary Research
8.5.3 Market Size and Revenue Forecasts
8.5.4 Pipeline Analysis
8.5.5 Competitive Landscape

List of Tables:

Table 1: Cancer Immunotherapies Market, Global, Epidemiology of Key Oncology Indications, 2016
Table 2: Cancer Immunotherapies Market, Global, Regional Lymph Node and Metastasis Staging, 2016
Table 3: Cancer Immunotherapies Market, Global, Eastern Co-operative Oncology Group Criteria, 2016
Table 4: Cancer Immunotherapies Market, Global, Breast Cancer Histopathological and Molecular Classification, 2016
Table 5: Cancer Immunotherapies Market, US, Breast Cancer Stage at Diagnosis and Five-Year Relative Survival (%), 2016
Table 6: Cancer Immunotherapies Market, US, Ovarian Cancer Stage and Survival Rates (%), 2016
Table 7: Cancer Immunotherapies Market, US, Lung Cancer Stage at Diagnosis and Five-Year Relative Survival (%), 2016
Table 8: Cancer Immunotherapies Market, US, Ovarian Cancer Stage at Diagnosis and Five-year Relative Survival (%), 2016
Table 9: Cancer Immunotherapies Market, Global, Approved Indications for Rituxan, 2016
Table 10: Cancer Immunotherapies Market, Global, Approved Indications for Revlimid, 2016
Table 11: Cancer Immunotherapies Market, Global, Approved Indications for Yervoy, 2016
Table 12: Cancer Immunotherapies Market, Global, Approved Indications for Opdivo, 2016
Table 13: Cancer Immunotherapies Market, Global, Approved Indications for Keytruda, 2016
Table 14: Cancer Immunotherapies Market, Global, Approved Indications for Pomalyst, 2016
Table 15: Cancer Immunotherapies Market, Global, Approved Indications for Gardasil, 2016
Table 16: Cancer Immunotherapies Market, Global, Approved Indications for Provenge, 2016
Table 17: Cancer Immunotherapies Market, Global, Forecast Revenue by Company, 2016
Table 18: Cancer Immunotherapies Market, Global, Licensing Deals Valued above $500m, 2006-2016
Table 19: Cancer Immunotherapies Market, Global, Co-development Deals Valued above $100m, 2006-2016
Table 20: Cancer Immunotherapies Market, Global, Pipeline Products, Discovery, 2016
Table 21: Cancer Immunotherapies Market, Global, Pipeline Products, Preclinical, 2016
Table 22: Cancer Immunotherapies Market, Global, Pipeline Products, IND/CTA filed, 2016
Table 23: Cancer Immunotherapies Market, Global, Pipeline Products, Phase I, 2016
Table 24: Cancer Immunotherapies Market, Global, Pipeline Products, Phase II, 2016
Table 25: Cancer Immunotherapies Market, Global, Pipeline Products, Phase III, 2016
Table 26: Cancer Immunotherapies Market, Global, Pipeline Products, Pre-Registration, 2016
Table 27: Cancer Immunotherapies Market, Global, Pipeline Products, Unknown, 2016

List of Figures:

Figure 1: Cancer Immunotherapies Market, Global, Epidemiology Patterns for Breast Cancer, 2015-2023
Figure 2: Cancer Immunotherapies Market, Global, Epidemiology Patterns for Melanoma, 2015-2023
Figure 3: Cancer Immunotherapies Market, Global, Epidemiology Patterns for NSCLC, 2015-2023
Figure 4: Cancer Immunotherapies Market, Global, Epidemiology Patterns for Ovarian Cancer, 2015-2023
Figure 5: Cancer Immunotherapies Market, Global, NSCLC Molecular Characteristic Frequency (%)
Figure 6: Cancer Immunotherapies Market, Global, Key Marketed Products and Approved Indications, 2016
Figure 7: Cancer Immunotherapies Market, Global, Annual Revenue for Rituxan ($bn), 2006-2022
Figure 8: Cancer Immunotherapies Market, Global, Annual Revenue for Revlimid ($bn), 2006-2022
Figure 9: Cancer Immunotherapies Market, Global, Annual Revenue for Yervoy ($bn), 2011-2022
Figure 10: Cancer Immunotherapies Market, Global, Annual Revenue for Opdivo ($bn), 2014-2022
Figure 11: Cancer Immunotherapies Market, Global, Annual Revenue for Keytruda ($bn), 2014-2022
Figure 12: Cancer Immunotherapies Market, Global, Annual Revenue for Pomalyst ($bn), 2013-2022
Figure 13: Cancer Immunotherapies Market, Global, Annual Revenue for Gardasil ($bn), 2006-2022
Figure 14: Cancer Immunotherapies Market, Global, Annual Revenue for Provenge ($m), 2010-2022
Figure 15: Cancer Immunotherapies Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2016
Figure 16: Cancer Immunotherapies Market, Global, Pipeline for Cancer Immunotherapies by Stage of Development, Molecule Type and Program Type, 2016
Figure 17: Cancer Immunotherapies Market, Global, Pipeline for Key Cancers by Stage of Development, 2016
Figure 18: Cancer Immunotherapies Market, Global, Pipeline for Key Cancers by Molecule Type, 2016
Figure 19: Cancer Immunotherapies Market, Global, Pipeline for Cancer Immunotherapies by Molecular Target, 2016
Figure 20: Cancer Immunotherapies Market, Global, Pipeline for Key Cancers by Molecular Target, 2016
Figure 21: Cancer Immunotherapies Market, Global, Clinical Trial Attrition Rates by Stage of Development (%), 2006-2016
Figure 22: Cancer Immunotherapies Market, Global, Clinical Trial Attrition Rates by Stage of Development and Indication (%), 2006-2016
Figure 23: Cancer Immunotherapies Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecule Type (%), 2006-2016
Figure 24: Cancer Immunotherapies Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecular Target (%), 2006-2016
Figure 25: Cancer Immunotherapies Market, Global, Clinical Trial Duration by Stage of Development (months), 2006-2016
Figure 26: Cancer Immunotherapies Market, Global, Clinical Trial Duration by Stage of Development and Indication (months), 2006-2016
Figure 27: Cancer Immunotherapies Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006-2016
Figure 28: Cancer Immunotherapies Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2006-2016
Figure 29: Cancer Immunotherapies Market, Global, Clinical Trial Size by Stage of Development (participants), 2006-2016
Figure 30: Cancer Immunotherapies Market, Global, Clinical Trial Size by Stage of Development and Indication (participants), 2006-2016
Figure 31: Cancer Immunotherapies Market, Global, Clinical Trial Size by Stage of Development and Molecule Type (participants), 2006-2016
Figure 32: Cancer Immunotherapies Market, Global, Clinical Trial Size by Stage of Development and Molecular Target (participants), 2006-2016
Figure 33: Cancer Immunotherapies Market, Global, Clinical Program Size by Stage of Development (participants), 2006-2016
Figure 34: Cancer Immunotherapies Market, Global, Clinical Program Size by Stage of Development and Indication (participants), 2006-2016
Figure 35: Cancer Immunotherapies Market, Global, Clinical Program Size by Stage of Development and Molecule Type (participants), 2006-2016
Figure 36: Cancer Immunotherapies Market, Global, Clinical Program Size by Stage of Development and Molecular Target (participants), 2006-2016
Figure 37: Cancer Immunotherapies Market, Global, Revenue for Durvalumab ($bn), 2017-2022
Figure 38: Cancer Immunotherapies Market, Global, Revenue for Durvalumab and Tremelimumab ($bn), 2018-2022
Figure 39: Cancer Immunotherapies Market, Global, Revenue for Tisagenlecleucel-T ($bn), 2017-2022
Figure 40: Cancer Immunotherapies Market, Global, Revenue for KTE-C19 ($m), 2017-2022
Figure 41: Cancer Immunotherapies Market, Global, Revenue for Avelumab ($m), 2017-2022
Figure 42: Cancer Immunotherapies Market, Global, Revenue for Epacadostat ($m), 2018-2022
Figure 43: Cancer Immunotherapies Market, Global, Market Size ($bn), 2015-2022
Figure 44: Cancer Immunotherapies Market, Global, Annual Revenue Forecast for Key Products ($m), 2015-2022
Figure 45: Cancer Immunotherapies Market, Global, Annual Revenue by Premium and Generic Products ($bn), 2015-2022
Figure 46: Cancer Immunotherapies Market, Global, Annual Revenue Forecast for Immune-Checkpoint Proteins ($bn), 2015-2022
Figure 47: Cancer Immunotherapies Market, Global, Annual Revenue Forecast for Tumor Associated Antigens ($bn), 2015-2022
Figure 48: Cancer Immunotherapies Market, Global, Annual Revenue Forecast for Cancer Vaccines ($bn), 2015-2022
Figure 49: Cancer Immunotherapies Market, Global, Annual Revenue Forecast for Signal Transduction ($bn), 2015-2022
Figure 50: Cancer Immunotherapies Market, Global, Company Analysis Matrix, 2015-2022
Figure 51: Cancer Immunotherapies Market, Global, Forecast Market Share by Company (%), 2015-2022
Figure 52: Cancer Immunotherapies Market, Global, Companies by Compound Annual Growth Rate (%), Base Year-2022
Figure 53: Cancer Immunotherapies Market, Global, Revenue by Product Type, 2015-2022
Figure 54: Cancer Immunotherapies Market, Global, Celgene Annual Revenue Forecast ($bn), 2015-2022
Figure 55: Cancer Immunotherapies Market, Global, Bristol-Myers Squibb Annual Revenue ($bn), 2015-2022
Figure 56: Cancer Immunotherapies Market, Global, Roche Annual Revenue ($bn), 2015-2022
Figure 57: Cancer Immunotherapies Market, Global, Merck & Co. Annual Revenue ($bn), 2015-2022
Figure 58: Cancer Immunotherapies Market, Global, AstraZeneca Annual Revenue ($bn), 2017-2022
Figure 59: Cancer Immunotherapies Market, Global, Novartis Annual Revenue ($bn), 2015-2022
Figure 60: Cancer Immunotherapies Market, Global, Amgen Annual Revenue ($bn), 2015-2022
Figure 61: Cancer Immunotherapies Market, Global, Pfizer Annual Revenue ($bn), 2016-2022
Figure 62: Cancer Immunotherapies Market, Global, Kite Pharma Annual Revenue ($m), 2017-2022
Figure 63: Cancer Immunotherapies Market, Global, Cluster by Growth and Market Share, 2015-2022
Figure 64: Cancer Immunotherapies Market, Global, Companies by Type, 2016
Figure 65: Cancer Immunotherapies Market, Global, High-Activity and Late-Stage Developers by Level of Specialization, 2016
Figure 66: Cancer Immunotherapies Market, Global, Proportion of Total Company Revenue Attributed to Cancer Immunotherapies, 2015-2022
Figure 67: Cancer Immunotherapies Market, Global, Licensing Deals by Region, Year and Value, 2006-2016
Figure 68: Cancer Immunotherapies Market, Global, Licensing Deals by Indication and Value, 2006-2016
Figure 69: Cancer Immunotherapies Market, Global, Licensing Deals by Stage of Development and Value, 2006-2016
Figure 70: Cancer Immunotherapies Market, Global, Licensing Deals by Molecule Type and Target, 2006-2016
Figure 71: Cancer Immunotherapies Market, Global, Co-development Deals by Region, Year and Value, 2006-2016
Figure 72: Cancer Immunotherapies Market, Global, Co-development Deals by Indication, 2006-2016
Figure 73: Cancer Immunotherapies Market, Global, Co-development Deals by Stage of Development and Value, 2006-2016
Figure 74: Cancer Immunotherapies Market, Global, Co-development Deals by Molecule Type and Target, 2006-2016

Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Amgen
  • AstraZeneca
  • Bristol-Myers Squibb
  • Celgene
  • Kite Pharma
  • Merck & Co.
  • MORE

The market size for cancer immunotherapies is expected to grow more than fourfold from $16.9 billion in 2015 to $75.8 billion by 2022, representing a rapid compound annual growth rate (CAGR) of 23.9%.

The company’s latest report states that there are currently 2,037 products in active development in the cancer immunotherapy pipeline, equating to 37% of the entire oncology pipeline, and reflecting the strong interest in this class of therapy in product development.

Yasser Mushtaq, a Senior Analyst, explains: “Although the cancer immunotherapy pipeline is clearly strong, a significant proportion is made up of early-stage products, namely those from the Discovery stage to Phase I. This is indicative of the difficulty associated with progressing cancer immunotherapies from preclinical laboratory studies to clinical application in humans.

“The imbalance between early-stage and late-stage product development is more pronounced than typically seen in the industry, and may suggest greater difficulty than normal in developing cancer immunotherapies. However, these findings may also indicate a substantial drive to invest in early-stage cancer immunotherapy development, which could eventually filter through to late-stage product development.”

According to the research, several late-stage pipeline drugs, as well as some already marketed drugs, are expected to achieve blockbuster status by the end of the forecast period, while a number of existing blockbuster therapies are forecast to experience strong revenue growth.

Established immunotherapies, particularly Revlimid, Opdivo, Keytruda and Gazyva, are set to witness rapid sales growth throughout the forecast period, with Keytruda and Opdivo rising by $7 billion and $9 billion, respectively. Revlimid will experience similar levels of growth, driven by label expansions covering oncology indications, including multiple forms of leukemia and lymphoma.

Mushtaq adds: “A number of pipeline products are also forecast to be approved by 2022, some of which are expected to be commercial successes. AstraZeneca’s durvalumab and tremelimumab, in development as individual therapies and in combination, will be the most notable products.

  • Comments provided by Yasser Mushtaq, Senior Analyst.
  • Information based on the report: Global Cancer Immunotherapies Market to 2022 - Immune Checkpoint Inhibitors and Therapeutic Cancer Vaccines to Characterize Increasingly Competitive Market.
  • This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by a team of industry experts.
Note: Product cover images may vary from those shown
5 of 6
  • Amgen
  • AstraZeneca
  • Bristol-Myers Squibb
  • Celgene
  • Kite Pharma
  • Merck & Co.
  • Novartis
  • Pfizer
  • Roche
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll